| For: | Li D, Gruber SB, Iyer S, Gupta S, Tejani M. Real-world clinical effectiveness of sorafenib among patients with unresectable hepatocellular carcinoma at two centers in the United States. World J Gastrointest Oncol 2023; 15(10): 1796-1806 [PMID: 37969411 DOI: 10.4251/wjgo.v15.i10.1796] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v15/i10/1796.htm |
| Number | Citing Articles |
| 1 |
A. Dalbeni, F. Cattazzo, L. A. Natola, M. Zoncapè, D. Faccincani, B. Stefanini, F. Ravaioli, R. Villani, A. Auriemma, D. Sacerdoti. What can real-world data teach us about treating patients with unresectable hepatocellular carcinoma?. Expert Review of Gastroenterology & Hepatology 2025; 19(4) doi: 10.1080/17474124.2025.2476541
|
| 2 |
Jirapat Wonglhow, Chirawadee Sathitruangsak, Patrapim Sunpaweravong, Panu Wetwittayakhlang, Arunee Dechaphunkul. Real-World Systemic Treatment Patterns, Survival Outcomes, and Prognostic Factors in Advanced Hepatocellular Carcinoma: A 15-Year Experience from a Low-Resource Setting. Cancers 2025; 17(17) doi: 10.3390/cancers17172729
|
| 3 |
Mahmoud Nazih, Ahmed I. Khoder, Imam Waked, Mohamed S. El Senbawy, Shimaa Abdelsattar, Sahar Badr Hassan, Mohamed Mahmoud Abdel-Latif. Real-world outcomes and predictive factors in hepatocellular carcinoma patients treated with sorafenib: an 18-month ambispective cohort analysis. Future Journal of Pharmaceutical Sciences 2025; 11(1) doi: 10.1186/s43094-025-00892-6
|
| 4 |
|
| 5 |
Xiaomo Xiong, Jeff Jianfei Guo. Cost Effectiveness of Tremelimumab Plus Durvalumab for Unresectable Hepatocellular Carcinoma in the USA. PharmacoEconomics 2025; 43(3) doi: 10.1007/s40273-024-01453-0
|
| 6 |
Tinashe A. Mazhindu, Vincent Nyangwara, Michalina A. Montaño, Edith Matsikidze, Onesai Chihaka, Charley Jang, Margaret Z. Borok, Collen Masimirembwa, Ntokozo Ndlovu. Albumin–Bilirubin Grade and HIV Status in Hepatocellular Carcinoma as Predictors of Survival in Zimbabwe. Livers 2026; 6(3) doi: 10.3390/livers6030049
|